HIF activation causes synthetic lethality between the VHL tumor suppressor & the EZH1 histone methyltransferase

Abhishek A. Chakraborty, Eijiro Nakamura, Jun Qi, Amanda Creech, Jacob D. Jaffe, Joshiawa Paulk, Jesse S. Novak, Kshithija Nagulapalli, Samuel K. Mcbrayer, Glenn S. Cowley, Javier Pineda, Jiaxi Song, Yaoyu E. Wang, Steven A. Carr, David E. Root, Sabina Signoretti, James E. Bradner, William G. Kaelin

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Inactivation of the von Hippel-Lindau tumor suppressor protein (pVHL) is the signature lesion in the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC). pVHL loss causes the transcriptional activation of hypoxia-inducible factor (HIF) target genes, including many genes that encode histone lysine demethylases. Moreover, chromatin regulators are frequently mutated in this disease. We found that ccRCC displays increased H3K27 acetylation and a shift toward mono- or unmethylated H3K27 caused by an HIF-dependent increase in H3K27 demethylase activity. Using a focused short hairpin RNA library, as well as CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-Associated protein 9) and a pharmacological inhibitor, we discovered that pVHL-defective ccRCC cells are hyperdependent on the H3K27 methyltransferase EZH1 for survival. Therefore, targeting EZH1 could be therapeutically useful in ccRCC.

Original languageEnglish (US)
Article numbereaal5272
JournalScience translational medicine
Issue number398
StatePublished - Jul 12 2017
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'HIF activation causes synthetic lethality between the VHL tumor suppressor & the EZH1 histone methyltransferase'. Together they form a unique fingerprint.

Cite this